Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls

Conclusions:
These core CSF biomarkers remained stable over 6 and 12 months in patients with early PD and HC. PD medication use may influence CSF α-syn. Novel biomarkers are needed to better profile progressive neurodegeneration in PD.

Source: Neurology - November 6, 2017 Category: Neurology Authors: Mollenhauer, B., Caspell-Garcia, C. J., Coffey, C. S., Taylor, P., Shaw, L. M., Trojanowski, J. Q., Singleton, A., Frasier, M., Marek, K., Galasko, D., For the Parkinson's Progression Marker Initiative Tags: Outcome research, Parkinson's disease/Parkinsonism, Cohort studies ARTICLE Source Type: research